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ABSTRACT
 Objective: Hypoparathyroidism is characterized 
by inadequate parathyroid hormone (PTH), resulting in 
hypocalcemia, hyperphosphatemia, and bone abnormali-
ties. Adults with hypoparathyroidism treated with recom-
binant human PTH, rhPTH(1-84), in the 24-week, phase 
III REPLACE study maintained serum calcium despite 
reductions in oral calcium and active vitamin D. This study 
assessed the long-term efficacy and safety of rhPTH(1-84) 
for hypoparathyroidism.
 Methods: This was a 24-week, open-label, flexible-
dose extension study of REPLACE (REPEAT) conducted 
in 3 outpatient centers in Hungary. Patients who previously 
completed or enrolled in REPLACE received 50 mg/day 
rhPTH(1-84), escalated to 75 and then to 100 mg/day, if 
needed, to reduce active vitamin D and oral calcium. The 
primary endpoint was ≥50% reduction in oral calcium (or 
≤500 mg/day) and active vitamin D (or calcitriol ≤0.25 mg/
day or alfacalcidol ≤0.50 mg/day) with normocalcemia.
 Results: Twenty-four patients (n = 16 previously 
treated with rhPTH[1-84]; n = 8 rhPTH[1-84]-naïve) 
were enrolled and completed the study. At Week 24, 75% 
of patients (95% confidence interval [CI], 53.3-90.2%) 
achieved the study endpoint; 58% eliminated oral calcium 
and active vitamin D. Urinary calcium, serum phosphate, 
and calcium × phosphate (Ca × P) product decreased by 
Week 24. Mean serum bone turnover markers increased 
with rhPTH(1-84). Treatment-emergent adverse events 
(TEAEs) were reported by 92% of patients. No serious 
adverse events (AEs) occurred.
 Conclusion: This study used a simplified treatment 
algorithm intended to better mimic typical clinical prac-
tice and demonstrated the extended efficacy and safety 
of rhPTH(1-84) in patients with hypoparathyroidism and 
confirmed the REPLACE findings. Sustained rhPTH(1-
84) efficacy up to 48 weeks was observed despite treat-
ment interruption between studies. (Endocr Pract. 
2016;22:000-000)
Abbreviations:
AE = adverse event; BMD = bone mineral density; 
BSAP = bone-specific alkaline phosphatase; BTM = 
bone turnover marker; Ca × P product = calcium × 
phosphate product; CTX = cross-linked C-telopeptide 
of type 1 collagen; OCN = osteocalcin; 25(OH)D = 
25-hydroxyvitamin D; P1NP = aminoterminal propep-
tide of type 1 collagen; PTH = parathyroid hormone; 
rhPTH(1-84) = recombinant human parathyroid 
hormone; TEAE = treatment-emergent adverse event; 
ULN = upper limit of normal.
INTRODUCTION
 Hypoparathyroidism is a rare disease characterized by 
absent or deficient levels of parathyroid hormone (PTH) 
in the circulation, resulting in impaired mineral homeo-
stasis (1,2). Hypoparathyroidism is often managed with 
high doses of oral calcium and active vitamin D to miti-
gate symptoms (2-4). However, this treatment strategy 
can result in hypercalcemia and hypercalciuria, which 
are associated with nephrolithiasis, nephrocalcinosis, and 
renal failure (2). Recombinant human PTH, rhPTH(1-84) 
(Natpara®; NPS Pharmaceuticals, Inc, Bedminster, NJ), is 
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full-length PTH produced by recombinant DNA technol-
ogy that was recently approved in the U.S. as an adjunct to 
oral calcium and active vitamin D to control hypocalcemia 
in adults with hypoparathyroidism. The REPLACE study 
was a randomized, placebo-controlled, double-blind, phase 
III trial that assessed the efficacy and safety of a flexible 
once-daily dosing regimen of rhPTH(1-84) in adults with 
hypoparathyroidism (5). After 24 weeks of treatment, 53% 
of patients treated with rhPTH(1-84) compared with 2% 
of placebo-treated patients achieved the efficacy endpoint 
of the study (P<.0001), which was composed of 3 criteria: 
(1) a ≥50% reduction of oral calcium dose from baseline; 
(2) a ≥50% reduction of active vitamin D dose; and (3) 
maintenance of albumin-corrected serum calcium levels, 
ideally within the target range of 8.0 to 9.0 mg/dL (2.0-
2.2 mmol/L; specifically ≥ baseline and ≤ upper limit of 
normal [ULN] of the laboratory) (5). Adverse events (AEs) 
were consistent with the disease state of hypoparathyroid-
ism and its treatment; the most common AEs were hypo-
calcemia, muscle spasms, and paresthesia (5). 
 The REPEAT study was a phase III, 24-week open-
label extension of the REPLACE study that included 
patients who had completed REPLACE or had been 
optimized but not randomized in REPLACE. The aim of 
the study was to assess the ongoing safety and extended 
benefits of rhPTH(1-84) in patients with hypoparathyroid-
ism. This article reports the efficacy and safety results of 
the REPEAT study and highlights the findings of examin-
ing changes in bone turnover markers (BTMs) and bone 
mineral density (BMD).
METHODS 
Study Patients and Design
 This phase III study was a 6-month open-label exten-
sion of REPLACE conducted in adult patients receiving 
rhPTH(1-84) for the treatment of hypoparathyroidism (Fig. 
1). Patients who completed the 24-week treatment course 
and the 4-week follow-up period in the REPLACE study 
or who had enrolled in REPLACE but dropped out during 
optimization before randomization were eligible for the 
current study provided that they met the REPLACE study 
eligibility criteria (5). In addition, patients enrolling in the 
REPEAT study must not have received rhPTH(1-84) or 
PTH(1-34) (Forteo®; Lilly USA, LLC, Indianapolis, IN) 
within 1 week before the baseline assessment and must 
have maintained serum 25-hydroxyvitamin D (25[OH]D) 
≤1.5 times the ULN for approximately 16 weeks before 
randomization. Patients with active malignancy, parathy-
roid carcinoma, or thyroid cancer within 5 years of entry 
were excluded from the study. 
 Initially, patients received 50 mg rhPTH(1-84) subcu-
taneously once daily. Dose titrations in 25-mg increments 
were permitted at each study visit through Week 16 (maxi-
mum allowed dose of 100 mg daily), with the goal of achiev-
ing or maintaining total serum calcium levels in the range 
of 8.0 to 9.0 mg/dL (2.0-2.2 mmol/L). Downtitration of 
rhPTH(1-84) dose was allowed at any point to a minimum 
of 50 mg/day. Sufficient supplemental native vitamin D was 
administered to maintain patients’ serum 25-hydroxyvita-
min D (25(OH)D) level in the normal range. Supplemental 
calcium and calcitriol/alfacalcidol regimens were adjusted 
based on total serum calcium levels, with the goal being 
a reduction or removal of calcitriol/alfacalcidol treatment 
to the maximum degree clinically possible and a decrease 
in the prescribed oral calcium supplementation to ≤500 
mg daily. Changes in doses of supplemental calcium 
and calcitriol/alfacalcidol were made at the discretion of 
the investigator, based on individual patient needs and 
responses. Once a patient achieved stable serum calcium 
(target, 8.0-9.0 mg/dL [2.0-2.2 mmol/L]) with the mini-
mum possible dose of supplements, he or she was main-
tained at that rhPTH(1-84) dose. After the initial baseline 
visit, scheduled visits occurred at Weeks 2, 4, 8, 16, and 
24. At the end of study treatment, patients were returned 
to their previous supplemental calcium and calcitriol/alfa-
calcidol. A follow-up study visit occurred at the end of 
Week 25, and a follow-up phone call took place at the end 
of Week 28. The study was conducted in accordance with 
the applicable International Conference on Harmonisation 
guidelines and the Declaration of Helsinki, and is registered 
(ClinicalTrials.gov identifier NCT01455181; EudraCT 
Number: 2011-001265-40). All patients signed a written 
informed consent form approved by an independent ethics 
committee before initiating study procedures.
Study Endpoints
 The study endpoint was the percentage of patients who 
achieved all 3 criteria (referred to as the “study endpoint 
with triple criteria”) at Week 24: (1) ≥50% reduction from 
baseline in oral calcium dose or an oral calcium dose of 
≤500 mg/day, (2) ≥50% reduction from baseline in oral 
calcitriol/alfacalcidol dose or an oral calcitriol dose of 
≤0.25 mg/day or alfacalcidol dose of ≤0.50 mg/day, and (3) 
a total serum calcium concentration that was normalized 
or maintained (target, 8.0-9.0 mg/dL [2.0-2.2 mmol/L]) 
compared with the baseline value and did not exceed the 
ULN of the laboratory.
 Prespecified secondary and exploratory endpoints 
included changes in 24-hour urine calcium excretion from 
baseline and the proportion of patients who had a calci-
um-phosphate (Ca × P) product in the normal range (≤55 
mg2/dL2 [4.4 mmol2/L2]) at Week 24. Daily doses of oral 
calcium and calcitriol/alfacalcidol were obtained from site 
investigator prescription data and patient diary data. For 
analysis purposes, alfacalcidol doses were converted to 
calcitriol doses based on a conversion factor of one half: 
2 alfacalcidol = 1 calcitriol. Exploratory efficacy measure-
ments included the change from baseline of 4 serum BTMs: 
bone-specific alkaline phosphatase (BSAP), aminotermi-
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nal propeptide of type 1 collagen (P1NP), cross-linked 
C-telopeptide of type 1 collagen (CTX), and osteocalcin 
(OCN). BMD measured by dual-energy x-ray absorpti-
ometry was determined in the lumbar vertebrae (L1-L4), 
the hip, and the distal one-third of the radius. Efficacy data 
are presented as mean ± SD. Safety endpoints included the 
incidence of AEs and serious AEs (SAEs), as well as clini-
cal laboratory test results.
Statistical Analysis
 The intention-to-treat population consisted of all 
patients who received at least 1 dose of study drug and had 
1 efficacy measurement. The safety population included all 
patients who received at least 1 dose of study drug with 
any follow-up information. Descriptive statistics were 
used to summarize the absolute values and change from 
baseline in safety and efficacy variables. This study was 
not sufficiently powered to determine the statistical signifi-
cance of safety or efficacy endpoints. For safety and most 
efficacy endpoints (except BMD), baseline was defined as 
the beginning of treatment with rhPTH(1-84). For patients 
who received rhPTH(1-84) in REPLACE, baseline was 
Visit 1 of the REPLACE study, whereas for patients who 
received placebo in REPLACE or enrolled in REPLACE 
but dropped out during optimization before randomization, 
Visit 1 of the REPEAT study served as baseline. For BMD 
analyses, measurements obtained at the end of REPLACE 
(for all patients who participated in REPLACE) or the 
beginning of REPEAT (for patients who enrolled directly 
into REPEAT) were used as baseline values.
RESULTS
Study Patients
 Twenty-four patients were enrolled for this study from 
3 sites in Hungary (Fig. 1). Twenty-three had completed 
the REPLACE study (treatment arms in REPLACE: 
rhPTH[1-84], n = 16; placebo, n = 7), and 1 patient 
enrolled directly into REPEAT after randomization into the 
REPLACE study closed. A mean ± SD of 9.9 ± 3.6 weeks 
elapsed between the end of treatment in REPLACE to the 
beginning of treatment in REPEAT. All enrolled patients 
completed the REPEAT study. Patient demographics and 
baseline characteristics are shown in Table 1. The major-
ity of the study population developed hypoparathyroidism 
following surgery, and half of enrolled patients had hypo-
parathyroidism for >10 years.
Efficacy Endpoints
 At Week 24, 75% of patients (95% confidence interval 
[CI], 53.3-90.2%) achieved the study endpoint with triple 
criteria (≥50% reduction in oral calcium dose or oral calci-
um dose of ≤500 mg/day, ≥50% reduction in oral calcitriol/
alfacalcidol dose or oral calcitriol dose of ≤0.25 mg/day or 
alfacalcidol dose ≤0.50 mg/day, and total serum calcium 
concentration that was normalized or maintained). Similar 
results were obtained when albumin-corrected serum calci-
um rather than total serum calcium was used to calculate 
the study endpoint (response rate, 71% [95% CI, 48.9-
87.4%]). Supportive analyses based on the components of 
the study endpoint also demonstrated benefits for patients 
Fig. 1. The REPEAT study design. rhPTH(1-84) = recombinant human parathyroid hormone.
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Table 1
Patient Demographics and Baseline Characteristics
Parameter
rhPTH(1-84)
(n = 24)
Age at screening, years
Mean ± SD 52.7 ± 10.9
Median 56.0
Min, max 29, 69
Sex, n (%)
Female 21 (87.5)
Male 3 (12.5)
Race, n (%)
White 24 (100)
Body mass index, kg/m2
Mean ± SD 29.8 ± 5.4
 Prescribed calcitriol, n (%)a
     Low dose, 0-0.25 mg/day 0
     Medium dose, >0.25-0.5 mg/day 2 (8)
     High dose, >0.5 mg/day 22 (92)
 Prescribed calcium, n (%)
     0-2,000 mg/day 22 (92)
     >2,000 mg/day 2 (8)
Cause of hypoparathyroidism, n (%)
Postsurgical 20 (83)
Benign thyroid condition, n 15
Thyroid cancer, n 4 
Unknown, n 1
Idiopathic 3 (13)
Unknown 1 (4)
 Duration of hypoparathyroidism, years
     Mean ± SD 15.1 ± 12.6
 Duration of hypoparathyroidism, n (%)
     ≤5 years 4 (17)
     >5-10 years 8 (33)
     >10 years 12 (50)
Previously treated with rhPTH(1-84) in REPLACE, 
n (%)
16 (67)
Time elapsed between end of treatment in 
REPLACE to beginning of REPEAT, weeks
Mean ± SD 9.9 ± 3.6
Min, max 4.1, 15.9
Abbreviation: rhPTH(1-84) = recombinant human parathyroid hormone. 
a Alfacalcidol dose converted to calcitriol dose based on a conversion factor of one half: 2 alfacalcidol = 1 calcitriol.
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treated with rhPTH(1-84). Mean oral calcium and calcitri-
ol/alfacalcidol doses were reduced with rhPTH(1-84) 
(Fig. 2). During the first 8 weeks of the study, mean ± SD 
oral calcium doses decreased progressively from baseline 
values of 1,687.5 ± 548.0 to 447.9 ± 477.7 mg/day (change 
from baseline, –72 ± 33%). Between Weeks 8 and 24, 
oral calcium doses were relatively stable, yielding a final 
oral calcium dose of 333.3 ± 540.1 mg/day (change from 
baseline, –76 ± 41%). A similar pattern was observed for 
calcitriol/alfacalcidol doses. The mean baseline calcitriol/
alfacalcidol dose of 1.13 ± 0.42 mg/day was reduced by 97 
± 8% to 0.04 ± 0.10 mg/day at Week 8 and then maintained 
near this level through Week 24. The final dose of calcitriol/
alfacalcidol was 0.02 ± 0.10 mg/day, a change from base-
line of –98 ± 10%. By Week 24, 14 (58%) patients discon-
tinued oral calcium, and 23 (96%) discontinued calcitriol/
alfacalcidol. Fourteen (58%) patients eliminated both oral 
calcium and calcitriol/alfacalcidol. During the study, 16 
(67%) patients received concomitant cholecalciferol.
 Substantial decreases in supplemental calcitriol/alfa-
calcidol doses with rhPTH(1-84) were accompanied by 
decreases from baseline in mean serum 25(OH)D levels. 
At baseline, the mean serum 25(OH)D was 38.9 ± 8.1 ng/
mL (97.1 ± 20.1 nmol/L), which decreased to 24.5 ± 6.8 
ng/mL (61.2 ± 16.9 nmol/L) at Week 4. By Week 24 mean 
serum 25(OH)D reached 30.5 ± 7.2 ng/mL (76.1 ± 17.9 
nmol/L; change from baseline, –8.4 ± 10.6 ng/mL [–21.0 ± 
26.4 nmol/L]).
 Total serum and urinary calcium levels decreased with 
rhPTH(1-84) treatment. At baseline, the mean total serum 
calcium level was 9.1 ± 0.9 mg/dL (2.3 ± 0.2 mmol/L), 
slightly above the target range of 8.0 to 9.0 mg/dL (2.0-2.2 
mmol/L), and 24-hour urinary calcium excretion was 368.4 
± 197.8 mg/24 hours (9.2 ± 4.9 mmol/24 hours). By Week 
24, total serum calcium had fallen to within the target range 
(8.8 ± 0.9 mg/dL [2.2 ± 0.2 mmol/L]; change from base-
line, –2.3 ± 11%) (Fig. 3). At the same time, urinary calci-
um excretion decreased to 330.7 ± 234.4 mg/24 hours (8.3 
± 5.8 mmol/24 hours), representing a –5.1 ± 60% change 
from baseline.
 Treatment with rhPTH(1-84) was associated with 
reductions in serum phosphate and Ca × P product levels. 
Mean serum phosphate levels were 4.7 ± 0.6 mg/dL (1.5 
± 0.2 mmol/L) at baseline and decreased to 4.0 ± 0.8 mg/
dL (1.3 ± 0.3 mmol/L) at Week 24, a mean change of –0.7 
± 0.7 mg/dL (–0.2 ± 0.2 mmol/L). Similarly, mean Ca × P 
product decreased by –7.8 ± 7.0 mg2/dL2 (0.6 ± 0.6 mmol2/
L2) during the study, from a baseline value of 42.6 ± 7.7 
mg2/dL2 (3.4 ± 0.6 mmol2/L2) to 34.8 ± 6.0 mg2/dL2 (2.8 ± 
0.5 mmol2/L2) at Week 24. During the course of the study, 
2 patients had >55 mg2/dL2 (>4.4 mmol2/L2) Ca × P prod-
uct levels (normal range ≤55 mg2/dL2 [≤4.4 mmol2/L2]): 1 
patient at baseline and the other patient at Week 2. These 2 
incidences were transient, and both of the affected patients 
met the study endpoint with triple criteria.
 At baseline, mean levels of serum BTMs were with-
in normal limits, with the exception of OCN, which was 
below normal. Baseline levels were 8.9 ± 2.3 mg/L for 
BSAP, 224.6 ± 138.0 ng/L for CTX, 33.3 ± 16.9 mg/L for 
P1NP, and 3.8 ± 1.9 mg/L for OCN. All serum BTMs rose 
during the study; at Week 24, mean serum levels were 30.1 
± 15.8 mg/L for BSAP, 876.3 ± 462.4 ng/L for CTX, 246.7 
± 126.4 mg/L for P1NP, and 31.5 ± 25.2 mg/L for OCN 
(Fig. 4A). Baseline levels of serum BTMs were similar in 
patients who received rhPTH(1-84) in both REPLACE and 
REPEAT compared with patients who received rhPTH(1-
84) in REPEAT only. However, increases in BSAP, CTX, 
and P1NP tended to be greater in patients who received 
rhPTH(1-84) during REPEAT only, with the exception of 
OCN, which showed similar changes from baseline in both 
groups (Fig. 4B).
 Between baseline (measurements obtained for all 
patients at the end of REPLACE or the beginning of 
REPEAT for patients who enrolled directly into REPEAT) 
and Week 24, BMD values trended downward in the hip 
(total and femoral neck) but not in the lumbar spine or 
Fig. 2. Percentage change from baseline in oral calcium (A) and calcitriol/alfacalcidol (B) 
doses. Error bars represent SD.
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distal one-third of the radius (Table 2). However, when 
comparing patients who had been previously treated 
with rhPTH(1-84) in REPLACE with patients who were 
rhPTH(1-84)-naïve at the start of REPEAT, a trend toward 
decreased BMD values was observed among rhPTH(1-
84)-naïve patients at all locations except the distal one-third 
radius. In contrast, patients who had received rhPTH(1-84) 
in REPLACE had increased BMD values at all locations 
except the distal one-third radius. Among the study group 
as a whole, Z-scores comparing an individual’s bone densi-
ty with that of an average person of the same ethnicity, sex, 
and age showed minimal differences between baseline and 
Week 24 (change from baseline: total hip, 0.005 ± 0.382 [n 
= 22]; hip, femoral neck, –0.059 ± 0.518 [n = 22]; lumbar 
spine, 0.364 ± 0.672 [n = 22]; distal one-third radius, 0.093 
± 0.364 [n = 23]).
Safety Endpoints
 Treatment-emergent AEs (TEAEs) were reported 
by 22/24 patients (92%), with most being rated mild or 
moderate in severity. There were no deaths or SAEs report-
ed during the study, and no patients discontinued because 
of AEs. The most frequently reported TEAEs were hypo-
esthesia, muscle spasms, vitamin D decreased, hypercal-
cemia, fatigue, headache, and hypocalcemia. A complete 
summary of the incidences of TEAEs that occurred in ≥5% 
of patients is shown in Table 3. Five (21%) patients expe-
rienced TEAEs that were considered by investigators to be 
related to rhPTH(1-84) treatment, and all resolved within 7 
days (7 events of hypercalcemia; 5/7 were mild or moder-
ate events); no other TEAEs were deemed to be study-
drug related. Three patients had rhPTH(1-84) dose reduc-
tions to 50 mg every other day because of safety concerns 
over persistent hypercalcemia or increased serum calcium 
levels. Fourteen (58%) patients experienced a TEAE in the 
4-week posttreatment follow-up period; the most common 
were hypoesthesia (n = 9), muscle spasms (n = 4), and 
hypocalcemia (n = 3). 
DISCUSSION
 Compared with the phase III, placebo-controlled 
REPLACE trial of rhPTH(1-84) in patients with hypopara-
thyroidism (5), the REPEAT study design incorporated a 
simplified treatment algorithm with reduced frequency of 
study visits after rhPTH(1-84) titration and fewer study 
procedures per visit, intended to better mimic typical clini-
cal practice in this patient population. In addition, changes 
to doses of oral calcium and calcitriol/alfacalcidol were 
made at the discretion of the REPEAT study investigators. 
Despite autonomy of the managing physicians regarding 
oral supplementation, it is evident from the data that the 
calcitriol doses were generally reduced before oral calci-
um. For example, calcitriol dose was decreased by a mean 
of 47% at Week 2 and 97% at Week 8. In contrast, oral 
calcium doses were reduced by a mean of 8% and 72% 
Fig. 3. Change in mean serum calcium during treatment with rhPTH(1-84). Error bars represent 
SDs, and the reference lines indicate the normal range of total serum calcium (i.e., 8.6-10.2 mg/dL). 
rhPTH(1-84) = recombinant human parathyroid hormone.
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Table 2
Change From Baseline in BMD at Week 24a
BMD, g/cm2
Location
All study patients
(N = 24)
Previously treated 
with rhPTH(1-84) in 
REPLACE (n = 16)
rhPTH(1-84)-naïve at 
start of REPEAT (n = 8)
Hip 
     Total –0.006 ± 0.048b 0.011 ± 0.052c –0.035 ± 0.019d
     Femoral neck –0.014 ± 0.066b 0.011 ± 0.067c –0.057 ± 0.036d
Lumbar spine 0.035 ± 0.079b  0.057 ± 0.083e –0.012 ± 0.042f
Distal one-third radius 0.002 ± 0.031g –0.008 ± 0.029e 0.019 ± 0.030d
Abbreviations: BMD = bone mineral density; rhPTH(1-84) = recombinant human parathyroid hormone. 
a Values are mean ± SD. Baseline values were obtained at the end of REPLACE (for patients who participated in 
REPLACE) or the beginning of REPEAT (for patients who enrolled directly into REPEAT).
b n = 22
c n = 14
d n = 8
e n = 15
f n = 7
g n = 23
Fig. 4. Change from baseline in bone turnover marker levels at Week 24. The mean values for BSAP, CTX, P1NP, and OCN at 
baseline and at Week 24 are plotted for the study group as a whole (A) and by duration of treatment with rhPTH(1-84) (B). Error 
bars represent SD. BSAP = bone-specific alkaline phosphatase; CTX = cross-linked C-telopeptide of type 1 collagen; OCN = 
osteocalcin; P1NP = aminoterminal propeptide of type 1 collagen; rhPTH(1-84) = recombinant human parathyroid hormone.
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Table 3
Summary of TEAEs in ≥5% of the Safety Population
MedDRA system organ class preferred terma Patients, n (%) N = 24
Number of 
events
Any TEAEb
No 2 (8.3)
Yes 22 (91.7) 87
Nervous system disorders
     Hypoesthesia 12 (50.0) 23
     Headache 4 (16.7) 5
     Paresthesia 2 (8.3) 3
Metabolism and nutrition disorders
     Hypercalcemia 5 (20.8) 7
     Hypocalcemia 4 (16.7) 4
     Tetany 3 (12.5) 3
Musculoskeletal and connective tissue disorders
     Muscle spasms 6 (25.0) 8
     Arthralgia 3 (12.5) 3
     Pain in the extremity 2 (8.3) 2
Gastrointestinal disorders
     Hypoesthesia oral 3 (12.5) 4
     Abdominal pain upper 2 (8.3) 3
     Nausea 2 (8.3) 2
Investigations
     25(OH)D decreased 6 (25.0) 6
General disorders and administration site conditions
     Fatigue 4 (16.7) 6
Renal and urinary disorders
     Polyuria 2 (8.3) 3
Respiratory, thoracic, and mediastinal disorders
     Dyspnea 2 (8.3) 2
Skin and subcutaneous tissue disorders
     Hypoesthesia facial 2 (8.3) 3
Abbreviations: MedDRA = Medical Dictionary for Regulatory Activities; 25(OH)D = native 
25-hydroxyvitamin D; TEAE = treatment-emergent adverse event.
a Preferred terms were individually reported; no grouping of terms was done for this table.
b Patients with any TEAE in ≥5% incidence.
at the same time points. Decreasing calcitriol before oral 
calcium is a reasonable approach when initiating treat-
ment with a full-length version of PTH, which activates 
conversion of 25(OH)D into 1,25-dihydroxyvitamin D 
(1,25[OH]2D) (4). Although oral calcium supplementation 
was greatly reduced, patients were unlikely to be calcium 
deficient. Dietary calcium consumption was monitored and 
patients were encouraged to maintain a total calcium intake 
of 1,200 mg/day through a combination of diet and supple-
mentation. 
 Despite a reduced number of clinical visits in REPEAT 
as compared with the REPLACE study, 75% of enrolled 
patients achieved the study endpoint with triple criteria at 
Week 24. When albumin-corrected serum calcium rather 
than total serum calcium was used to calculate the study 
endpoint, 71% of study patients fulfilled the triple crite-
ria. This exceeds the percentage of patients who achieved 
a similar study endpoint with rhPTH(1-84) treatment in the 
REPLACE study (53%, calculated using albumin-correct-
ed serum calcium) (5), indicating robust and consistent 
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effects of rhPTH(1-84) in patients with hypoparathyroid-
ism. In addition, for most patients who previously received 
rhPTH(1-84) in REPLACE, efficacy was sustained for up 
to 48 weeks of treatment, despite an average interruption 
in therapy of approximately 10 weeks for all REPLACE 
participants between studies.
 Treatment with rhPTH(1-84) was associated with a 
normalization of mineral homeostasis. Urinary calcium 
decreased toward normal during the study. In addition, 
total serum calcium decreased slightly to within the target 
range (8.0-9.0 mg/dL [2.0-2.2 mmol/L]) by Week 24, 
per the study treatment algorithm that directed investiga-
tors to adjust oral supplement doses in order to maintain 
appropriate serum calcium levels. During the same treat-
ment period, patients decreased their oral calcium doses 
by 76% and calcitriol/alfacalcidol doses by 97%. Together, 
these results indicate that rhPTH(1-84) treatment permitted 
greater renal calcium reabsorption, thereby allowing serum 
calcium to be maintained within the normal range despite 
substantial decreases in oral supplementation. At the same 
time, mean serum phosphate levels showed minor decreas-
es, and no Ca × P products above 55 mg2/dL2 (4.4 mmol2/
L2) were reported at Week 24. 
 In hypoparathyroidism, insufficient or absent endog-
enous PTH can lead to decreased bone turnover, increased 
BMD, and abnormal bone architecture (2). rhPTH(1-84) 
treatment in REPEAT was associated with an increase in 
mean serum BTMs in all patients, even when retreated with 
rhPTH(1-84), consistent with prior clinical studies report-
ing elevations of CTX, P1NP, and OCN after 6 months of 
rhPTH(1-84) treatment (6-8). Because the analyzed mark-
ers are indicative of both bone resorption (CTX) and bone 
formation (BSAP, P1PN, and OCN), these data suggest 
that rhPTH(1-84) induces an increase in bone turnover (9).
 Compared with patients who received rhPTH(1-
84) in REPLACE, patients who were rhPTH(1-84)-na-
ïve at the beginning of REPEAT experienced a more 
pronounced increase in BTMs at Week 24, even though 
baseline values were determined at the start of rhPTH(1-
84) treatment in both studies. These results are in agree-
ment with previous studies suggesting that BTM levels 
initially increase following treatment with rhPTH(1-84) 
or rhPTH(1-34), reach a plateau, and then decrease to 
levels that are within the normal range but higher than 
baseline (6,7,10). Among patients with hypoparathy-
roidism treated with 100 mg rhPTH(1-84) every other 
day, BTM levels reach a maximum approximately 5 to 
12 months after treatment initiation and then begin to 
decline (6,7). In REPEAT, patients previously assigned 
to the rhPTH(1-84) arm of REPLACE had received 48 
weeks of therapy by the end of REPEAT. Therefore, it is 
not surprising that these patients, who had already passed 
the time period of peak serum BTMs with rhPTH(1-84), 
exhibited lower BTM levels at Week 24 of REPEAT 
compared with the rhPTH(1-84)-naïve cohort. 
 Among study patients as a whole, BMD measure-
ments showed minimal changes from baseline at Week 24. 
In contrast, patients treated with rhPTH(1-84) for 24 weeks 
in the REPLACE study exhibited significant decreases in 
BMD hip measurements (total hip and femoral neck) and 
trends toward decreased BMD at lumbar spine and distal 
one-third radius (11,12). The difference in BMD results 
between the 2 studies may be explained by the timing 
of baseline measurements. In REPEAT, baseline BMD 
values were obtained at the end of the REPLACE study 
or the beginning of the REPEAT study. Therefore, the 16 
patients who were previously treated with rhPTH(1-84) 
in REPLACE had already received 24 weeks of therapy 
before baseline BMD measurements for REPEAT. These 
patients showed minor increases in BMD values at 3 of 4 
locations at Week 24 in REPEAT. In contrast, among the 8 
patients who were rhPTH(1-84) naïve at the beginning of 
REPLACE, BMD measurements trended downward in all 
locations except the distal one-third radius. Together, the 
BTM and BMD data suggest that treatment with rhPTH(1-
84) improves bone remodeling in patients with hypopara-
thyroidism.
 The TEAEs reported in this study were consistent with 
the mechanism of action of rhPTH(1-84) and the underly-
ing disease state of hypoparathyroidism and were similar 
to those observed in REPLACE (5). Three (13%) patients 
experienced an AE of hypocalcemia in the 4-week post-
treatment study period despite the fact that study patients 
were returned to baseline levels of supplemental calcium 
and active vitamin D at the end of rhPTH(1-84) treatment. 
A similar phenomenon was observed in the REPLACE 
study (5), suggesting that withdrawal or interruption of 
rhPTH(1-84) may be a risk factor for the development of 
hypocalcemia AEs.
CONCLUSION
 This study was limited by its open-label, uncontrolled 
design and relatively small sample size, which precluded 
the ability to determine the statistical significance of safety 
or efficacy endpoints. Nonetheless, the results the extended 
efficacy and safety of rhPTH(1-84) in patients with hypo-
parathyroidism and confirms the findings of the REPLACE 
study (5). These results also contribute to findings demon-
strating that once-daily rhPTH(1-84) has many of the same 
physiologic effects of endogenous PTH, namely serum 
and urinary calcium control, lowered serum phosphate, 
decreased Ca × P product formation, and increased bone 
turnover.
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